Special Issue

New Insights into Liver Regeneration

Message from the Guest Editor

The journal *Biomedicines* is launching a Special Issue entitled "New Insights into Liver Regeneration", which aims to improve our current knowledge by publishing recent advances in liver regeneration. This Special Issue aims to provide insights into cellular and molecular mechanisms of hepatic regeneration upon injury, as well as highlighting the state-of-the-art knowledge on translational approaches to treat liver diseases. I cordially invite authors to submit high-quality basic and clinical original research and review articles on topics including, but not limited to:

- Acute and chronic liver injury;
- Liver regeneration under pathophysiological conditions:
- Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis;
- Inflammation:
- Acute phase response;
- Fibrosis;
- Cholestasis;
- Signaling pathways;
- Bile acids;
- Cytokines.

I look forward to receiving your contributions.

Guest Editor

Prof. Dr. Rania Dayoub

Department for Paediatric and Adolescent Medicine, University Hospital Regensburg, 93053 Regensburg, Germany

Deadline for manuscript submissions

closed (31 December 2023)



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/176234

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).